Soligenix SGX302 Psoriasis Treatment Trial FAQ

What is Soligenix developing for psoriasis treatment?

Soligenix is developing SGX302, a synthetic hypericin formulation, as a novel therapeutic option for mild-to-moderate psoriasis.

What stage of development is the SGX302 psoriasis treatment currently in?

SGX302 is currently in a phase 2a clinical trial (registered as NCT05442190) for mild-to-moderate psoriasis.

What previous results has SGX302 demonstrated?

SGX302 has already demonstrated positive results in a phase 1/2 pilot study and earlier proof-of-concept work showed encouraging signals.

What is the purpose of the current phase 2a trial?

The current study aims to further assess safety and biological activity of SGX302, as well as generate additional data to guide larger studies.

Why is this development significant for psoriasis patients?

Psoriasis remains a persistent challenge for millions worldwide, and promising new treatments like SGX302 could provide a novel therapeutic option for this prevalent autoimmune skin condition.

What type of company is Soligenix?

Soligenix is a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, and it’s positioning itself to expand its presence in dermatology.

Where can investors find the latest news and updates about Soligenix?

The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX.

What is the market potential for this psoriasis treatment?

The treatment addresses one of the most prevalent autoimmune skin conditions affecting millions of patients worldwide, representing significant market potential.

How does this development position Soligenix in the dermatology market?

Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for psoriasis, building on its focus on inflammatory conditions.